Press releases
-
-
-
Internal link ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025
-
-
-
-
-
-
-
-
-
Internal link ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
-
-
-
Internal link ProQR Announces Results for the Third Quarter of 2015 and Provides Update on Clinical Trials
-
-
-
Internal link ProQR Announces a Proof-of-Concept Nasal Potential Difference Study of QR-010 is Open for Enrollment
-
Internal link ProQR Announces Results for the Second Quarter of 2015
-
Internal link ProQR Announces Enrollment Has Started in Global Phase 1b Study of QR-010 in Cystic Fibrosis Patients
-
-
-
Internal link ProQR Therapeutics Announces Annual Shareholder Meeting
-
-